https://recursion.com

Pioneering AI Drug Discovery | RecursionDive into Recursion's innovative approach to decoding biology. Join our mission & explore what AI drug discovery companies can do. Contact us today!Pioneering AI Drug Discovery | Recursion Our PlatformMissionPlatformScientific MaterialsPipelineClinical TrialsView AllFAP - TUPELOSolid Tumors - ELUCIDATESolid Tumors & Lymphoma - DAHLIAB-cell Malignancies - EXCELERIZESolid Tumors - ENLYGHTSolid Tumors - ZINNIAPartnersInvestorsInvestor RelationsESGDownload DayCompany MaterialsAbout UsStoryTeamNewsPressBlogCareersThe AI engine uncovering novel medicines that matterFaster, better, and at scale for patients who are waitingLEARN HOWExplore our PlatformUnlocking the First Neuroscience Target for the Recursion and Genentech CollaborationRead moreDecoding biology to radically improve livesRecursion was founded more than a decade ago on the idea that we could take images of cells and use these images to train artificial intelligence to understand the vast unknown biological space – the cellular disruptions driving disease – to use AI-drug discovery to reduce the massive 90% failure rate of traditional drug discovery.Our missionTherapeutic AreaDisease IndicationPreclinicalIND-EnablingPhase 1/2Pivotal/Phase 3OncologySolid tumors and lymphoma OncologyAdvanced solid tumors OncologyB-cell malignancies OncologySolid tumors and hematology oncology OncologySolid tumors RareFamilial adenomatous polyposis RareHypophosphatasia Therapeutic AreaDisease IndicationPreclinicalIND-EnablingPhase 1/2Pivotal/Phase 3OncologyFamilial adenomatous polyposis OncologySolid tumors and lymphoma OncologyAdvanced solid tumors OncologyB-cell malignancies OncologySolid tumors and hematology oncology OncologySolid tumors OncologyHypophosphatasia Therapeutic AreaDisease IndicationPreclinicalIND-EnablingPhase 1/2Pivotal/Phase 3OncologyFamilial adenomatous polyposis OncologySolid tumors and lymphoma OncologyAdvanced solid tumors OncologyB-cell malignancies OncologySolid tumors and hematology oncology OncologySolid tumors OncologyHypophosphatasia Better medicines, through novel insights and precision designWe’re using data and AI to bring better medicines to patients, faster.

The Recursion OS drug discovery and development platform has yielded an advanced pipeline of potential first-in-class and best-in-class treatments for conditions with high unmet need including aggressive cancers and rare diseases. Today, we’ve demonstrated significant improvements in speed, efficiency, and reduced costs from hit identification to IND-enabling studies compared to traditional pharmaceutical company averages.Explore our pipelineDisease IndicationPreclinicalIND-EnablingPhase 1/2PivotalPhase 3Familial adenomatous polyposis Solid tumors and lymphoma Advanced solid tumors B-cell malignancies Solid tumors and hematology oncology Solid tumors Hypophosphatasia Better medicines, through novel insights and precision designWe’re using data and AI to bring better medicines to patients, faster.

The Recursion OS drug discovery and development platform has yielded an advanced pipeline of potential first-in-class and best-in-class treatments for conditions with high unmet need including aggressive cancers and rare diseases. Today, we’ve demonstrated significant improvements in speed, efficiency, and reduced costs from hit identification to IND-enabling studies compared to traditional pharmaceutical company averages.Explore our pipelineInside the loop: Learn how we map disease biology and design potential medicines, and carry them into the clinic — at scaleTake a look inside the automated labs that form our AI-native data factory to see our end-to-end drug discovery and development engine work as one connected system. Driven by bilingual teams of scientists and technologists, our wet and dry "lab-in-the-loop," forms a continuous learning system of physical automation and machine learning models. See how we run up to 2 million weekly experiments to build a 50+ petabyte proprietary dataset, tightly connecting biology, generative de novo chemistry, and translational clinical tools to systematically de-risk drug discovery.Explore our technologyDelivering for our partnersOur strategic partnerships allow us to accelerate the discovery of new medicines and expand our potential impact on patients via AI-drug discovery.This includes pharmaceutical partnerships with industry leaders, technology partnerships with computational titans, and next-generation data partnerships that enhance our capabilities and generative AI for pharma as one of the top AI drug discovery companies in the industry.Partner with RecursionThe latest from RecursionRecursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell LymphomasRead more →Leveraging the Power of Patient Data in AI-Drug DiscoveryRead more →Will AI ever cure cancer? The multibillion-dollar race to bring the first AI-discovered drug to marketRead more →Decoding biology to radically improve lives.®Proud founding member of BioHive, the fastest growing life sciences community in the nationGet In Touch41 S Rio Grande StreetSalt Lake City, UT 84101phone: (385) 269-0203info@recursion.comGet InvolvedCareersInvestor RelationsMedia KitPoliciesWebsite Terms of UsePrivacy PolicyVendor Expectations Manual & ResourcesAccessibilityConnect LinkedInX InstagramYoutubeFacebookBlueskyDecoding biology to radically improve lives.®Proud founding member of BioHive, the fastest growing life sciences community in the nationGet In Touch41 S Rio Grande StreetSalt Lake City, UT 84101phone: (385) 269-0203info@recursion.comGet InvolvedCareersInvestor RelationsMedia KitFAQPoliciesWebsite Terms of UsePrivacy PolicyVendor Expectations Manual & ResourcesAccessibilityConnect LinkedInX InstagramYoutubeFacebookBluesky© 2026 Recursion. All rights reserved.enen1790379123https://recursion.com

Editați site-ul dvs.?

ce faci?